In Vitro Activity of Ozenoxacin Against Quinolone-susceptible and Quinolone-resistant Gram-positive Bacteria

Overview

Journal Antimicrob Agents Chemother

Publisher American Society for Microbiology

Specialty Pharmacology

Date 2013 Oct 2

PMID 24080666

Citations 11

Authors

Y Lopez

M Tato

P Espinal

F Garcia-Alonso

D Gargallo-Viola

R Canton

J Vila

Affiliations

Soon will be listed here.

Abstract

In vitro activity of ozenoxacin, a novel nonfluorinated topical (L. D. Saravolatz and J. Leggett, Clin. Infect. Dis. 37:1210-1215, 2003) quinolone, was compared with the activities of other quinolones against well-characterized quinolone-susceptible and quinolone-resistant Gram-positive bacteria. Ozenoxacin was 3-fold to 321-fold more active than other quinolones. Ozenoxacin could represent a first-in-class nonfluorinated quinolone for the topical treatment of a broad range of dermatological infections.

Citing Articles

Ozenoxacin suppresses sebum production by inhibiting mTORC1 activation in differentiated hamster sebocytes.

Kitano T, Koiwai T, Fujikawa K, Mori S, Matsumoto T, Sato T J Dermatol. 2024; 51(9):1187-1198.

PMID: 39087744 PMC: 11483923. DOI: 10.1111/1346-8138.17409.

activity of ozenoxacin against and clinical isolates recovered in a worldwide multicentre study (2020-2022).

Garcia-Castillo M, Hernandez-Garcia M, Correa A, Coppi M, Griener T, Fritsche T JAC Antimicrob Resist. 2024; 6(3):dlae088.

PMID: 38872714 PMC: 11170484. DOI: 10.1093/jacamr/dlae088.

Green Nail Syndrome Treated with Ozenoxacin: Two Case Reports.

Cosio T, Petruccelli R, Gaziano R, Fontana C, Favaro M, Zampini P Case Rep Dermatol. 2023; 15(1):217-224.

PMID: 38023344 PMC: 10653707. DOI: 10.1159/000533923.

Staph wars: the antibiotic pipeline strikes back.

Douglas E, Laabei M Microbiology (Reading). 2023; 169(9).

PMID: 37656158 PMC: 10569064. DOI: 10.1099/mic.0.001387.

Uptake of Ozenoxacin and Other Quinolones in Gram-Positive Bacteria.

Lopez Y, Munoz L, Gargallo-Viola D, Canton R, Vila J, Zsolt I Int J Mol Sci. 2021; 22(24).

PMID: 34948159 PMC: 8708121. DOI: 10.3390/ijms222413363.

References

Almer L, Hoffrage J, Keller E, Flamm R, Shortridge V . In vitro and bactericidal activities of ABT-492, a novel fluoroquinolone, against Gram-positive and Gram-negative organisms. Antimicrob Agents Chemother. 2004; 48(7):2771-7. PMC: 434201. DOI: 10.1128/AAC.48.7.2771-2777.2004. View

Rice L . Antimicrobial resistance in gram-positive bacteria. Am J Med. 2006; 119(6 Suppl 1):S11-9. DOI: 10.1016/j.amjmed.2006.03.012. View

Zhang R, Eggleston K, Rotimi V, Zeckhauser R . Antibiotic resistance as a global threat: evidence from China, Kuwait and the United States. Global Health. 2006; 2:6. PMC: 1502134. DOI: 10.1186/1744-8603-2-6. View

Saravolatz L, Leggett J . Gatifloxacin, gemifloxacin, and moxifloxacin: the role of 3 newer fluoroquinolones. Clin Infect Dis. 2003; 37(9):1210-5. DOI: 10.1086/378809. View

Wiles J, Bradbury B, Pucci M . New quinolone antibiotics: a survey of the literature from 2005 to 2010. Expert Opin Ther Pat. 2010; 20(10):1295-319. DOI: 10.1517/13543776.2010.505922. View

Oyamada Y, Ito H, Fujimoto K, Asada R, Niga T, Okamoto R . Combination of known and unknown mechanisms confers high-level resistance to fluoroquinolones in Enterococcus faecium. J Med Microbiol. 2006; 55(Pt 6):729-736. DOI: 10.1099/jmm.0.46303-0. View

Biedenbach D, Toleman M, Walsh T, Jones R . Characterization of fluoroquinolone-resistant beta-hemolytic Streptococcus spp. isolated in North America and Europe including the first report of fluoroquinolone-resistant Streptococcus dysgalactiae subspecies equisimilis: report from the SENTRY.... Diagn Microbiol Infect Dis. 2006; 55(2):119-27. DOI: 10.1016/j.diagmicrobio.2005.12.006. View

Arai K, Hirakata Y, Yano H, Kanamori H, Endo S, Hirotani A . Emergence of fluoroquinolone-resistant Streptococcus pyogenes in Japan by a point mutation leading to a new amino acid substitution. J Antimicrob Chemother. 2010; 66(3):494-8. DOI: 10.1093/jac/dkq477. View

Bhagwat S, McGhee P, Kosowska-Shick K, Patel M, Appelbaum P . In vitro activity of the quinolone WCK 771 against recent U.S. hospital and community-acquired Staphylococcus aureus pathogens with various resistance types. Antimicrob Agents Chemother. 2008; 53(2):811-3. PMC: 2630593. DOI: 10.1128/AAC.01150-08. View

10.

Billal D, Fedorko D, Steve Yan S, Hotomi M, Fujihara K, Nelson N . In vitro induction and selection of fluoroquinolone-resistant mutants of Streptococcus pyogenes strains with multiple emm types. J Antimicrob Chemother. 2006; 59(1):28-34. DOI: 10.1093/jac/dkl428. View

11.

Yamakawa T, Mitsuyama J, Hayashi K . In vitro and in vivo antibacterial activity of T-3912, a novel non-fluorinated topical quinolone. J Antimicrob Chemother. 2002; 49(3):455-65. DOI: 10.1093/jac/49.3.455. View

12.

Yamada M, Yoshida J, Hatou S, Yoshida T, Minagawa Y . Mutations in the quinolone resistance determining region in Staphylococcus epidermidis recovered from conjunctiva and their association with susceptibility to various fluoroquinolones. Br J Ophthalmol. 2008; 92(6):848-51. PMC: 2771781. DOI: 10.1136/bjo.2007.129858. View

13.

Maina E, Kiiyukia C, Wamae C, Waiyaki P, Kariuki S . Characterization of methicillin-resistant Staphylococcus aureus from skin and soft tissue infections in patients in Nairobi, Kenya. Int J Infect Dis. 2012; 17(2):e115-9. DOI: 10.1016/j.ijid.2012.09.006. View

14.

Sierra J, Marco F, Ruiz J, Jimenez de Anta M, Vila J . Correlation between the activity of different fluoroquinolones and the presence of mechanisms of quinolone resistance in epidemiologically related and unrelated strains of methicillin-susceptible and -resistant Staphylococcus aureus. Clin Microbiol Infect. 2003; 8(12):781-90. DOI: 10.1046/j.1469-0691.2002.00400.x. View

15.

Chen Y, Liu C, Lu J, King C, Hsueh P . In vitro activity of nemonoxacin (TG-873870), a novel non-fluorinated quinolone, against clinical isolates of Staphylococcus aureus, enterococci and Streptococcus pneumoniae with various resistance phenotypes in Taiwan. J Antimicrob Chemother. 2009; 64(6):1226-9. DOI: 10.1093/jac/dkp370. View

16.

Ki M, Srinivasan U, Oh K, Kim M, Shin J, Hong H . Emerging fluoroquinolone resistance in Streptococcus agalactiae in South Korea. Eur J Clin Microbiol Infect Dis. 2012; 31(11):3199-205. DOI: 10.1007/s10096-012-1685-8. View